8-cpt-cyclic amp

8-CPT-Cyclic AMP (8-CPT-cAMP) sodium functions dually as a selective activator of cyclic AMP-dependent protein kinase (PKA) and as a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA), demonstrating an inhibitory concentration (IC 50) of 0.9 μM. Additionally, this compound inhibits PDE III and PDE IV, while significantly activating Epac, showcasing its diverse pharmacological activities [1] [2].

Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.2 By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.[2],[3]

Cyclic di-AMP (c-di-AMP) is a second messenger produced by bacteria but not by mammals. Generated by a family of diadenylate cyclases, c-di-AMP can impact bacterial cell growth, cell wall homeostasis, pathogenicity, and other cellular functions. Bacteria-derived cyclic dinucleotides, including c-di-AMP, trigger the expression of interferon genes in mammalian cells.

8-bromo-Cyclic AMP is a brominated derivative of cAMP that remains long-acting due to its resistance to degradation by cAMP phosphodiesterase. It can activate cAMP-dependent protein kinase, inhibiting growth, decreasing proliferation, increasing differentiation, and inducing apoptosis of cancer cells.

Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.

8-CPT-2Me-cAMP sodium is a sodium salt compound that selectively activates exchange proteins activated by cAMP (Epac). These Epac proteins are cAMP-sensitive guanine nucleotide exchange factors (GEFs) responsible for activating small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium specifically activates Epac1 with an EC50 value of 2.2 μM, while showing no activation of PKA with an EC50 value greater than 10 μM [1]. Additionally, 8-CPT-2Me-cAMP sodium stimulates the Epac-mediated release of calcium ions (Ca2+) in vitro in pancreatic β-cells [2].

Cyclic ADP-ribose (cADP-ribose) is a calcium mobilizing nucleotide that is biosynthesized from NAD+ by cADP-ribose synthases, including CD38. cADP-Ribose appears to activate calcium channels in intracellular membranes, which in turn activate ryanodine receptors. 8-bromo-cADP-Ribose is a stable, cell-permeable analog that blocks calcium release evoked by cADP-ribose in sea urchin egg homogenates with an IC50 value of 1.7 μM. It is commonly used to investigate intracellular signaling through cADP-ribose in isolated cells and tissues.

Sp-8-CPT-cAMPS is a powerful and specific cAMP analog that activates cAMP-dependent protein kinase A (PKA I and PKA II) selectively and effectively. It exhibits a 153-fold preference for site A of RI over site A of RII, and a 59-fold preference for site B of RII over site B of RI.

Cyclic AMP (cAMP) (Adenosine 3',5'-cyclophosphate) combined with vitamin C treatment of children with viral myocarditis has exact curative effect, and it can improve cardiac function of patients and improve immune function.

8-Bromo-AMP, also known as 8-Bromoadenosine 5'-monophosphate, is a membrane permeable cAMP analogue. It enhances cardiac recovery from ischemia and reperfusion by elevating ATP, ADP, and total adenine nucleotide concentrations.

Rp-8-CPT-cAMPS is a powerful and competitive antagonist of cAMP-induced activation of cAMP-dependent protein kinase (PKA) I and II. Acting as a potent cAMP analog, Rp-8-CPT-cAMPS exhibits a preference for site A of RI over site A of RII. Additionally, it favors site B of RII over site B of RI. This compound effectively inhibits cAMP-dependent PKA activation and demonstrates selectivity in binding to specific sites within the protein kinase.